Reata shares worth $241 after 'unequivocal upside win,' says Citi
Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $241 from $194 and reiterates the stock as a top pick with a Buy rating. The stock in premarket trading is up 34%, or $34.43, to $135.02. The registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia is a "best case scenario," Nochomovitz tells investors in a research note. The data are an "unequivocal upside win" for Reata, especially amidst very low expectations for the trial, says the analyst. He sees omaveloxolone as a $40-$50 per share opportunity for the company and moved his valuation to a 90% probability of success. This means Reata is now worth $241 per share, says the analyst.